ZA201000756B - Methods for recombinant manufacturing of anti-rsv antibodies - Google Patents

Methods for recombinant manufacturing of anti-rsv antibodies

Info

Publication number
ZA201000756B
ZA201000756B ZA2010/00756A ZA201000756A ZA201000756B ZA 201000756 B ZA201000756 B ZA 201000756B ZA 2010/00756 A ZA2010/00756 A ZA 2010/00756A ZA 201000756 A ZA201000756 A ZA 201000756A ZA 201000756 B ZA201000756 B ZA 201000756B
Authority
ZA
South Africa
Prior art keywords
methods
rsv antibodies
recombinant manufacturing
recombinant
manufacturing
Prior art date
Application number
ZA2010/00756A
Other languages
English (en)
Inventor
Anne Bondgaard Tolstrup
Johan Lantto
Finn C Wiberg
Lars Soegaard Nielsen
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of ZA201000756B publication Critical patent/ZA201000756B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2010/00756A 2007-09-07 2010-02-01 Methods for recombinant manufacturing of anti-rsv antibodies ZA201000756B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701289 2007-09-07
US97140407P 2007-09-11 2007-09-11
PCT/DK2008/050218 WO2009030237A2 (en) 2007-09-07 2008-09-04 Methods for recombinant manufacturing of anti-rsv antibodies

Publications (1)

Publication Number Publication Date
ZA201000756B true ZA201000756B (en) 2010-10-27

Family

ID=40297785

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/00756A ZA201000756B (en) 2007-09-07 2010-02-01 Methods for recombinant manufacturing of anti-rsv antibodies

Country Status (13)

Country Link
US (2) US20090137003A1 (enExample)
EP (1) EP2185590A2 (enExample)
JP (1) JP2011514139A (enExample)
KR (1) KR20100087283A (enExample)
CN (1) CN101821289A (enExample)
AU (1) AU2008295248A1 (enExample)
BR (1) BRPI0817079A2 (enExample)
CA (1) CA2695309A1 (enExample)
MX (1) MX2010002044A (enExample)
RU (1) RU2010113510A (enExample)
TW (1) TW200925279A (enExample)
WO (1) WO2009030237A2 (enExample)
ZA (1) ZA201000756B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2502628B1 (en) * 2006-06-23 2016-12-14 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
HRP20110686T1 (hr) * 2007-03-01 2011-10-31 Symphogen A/S Postupak kloniranja srodnih protutijela
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2010022738A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
US9855291B2 (en) 2008-11-03 2018-01-02 Adc Therapeutics Sa Anti-kidney associated antigen 1 (KAAG1) antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
ES2553440T3 (es) * 2009-08-13 2015-12-09 Crucell Holland B.V. Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
NZ599148A (en) * 2009-10-06 2014-08-29 Medimmune Ltd Rsv-specific binding molecule
CN104628850B (zh) * 2009-10-06 2020-07-28 医学免疫有限公司 Rsv-特异性结合分子
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN102711449B (zh) 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
KR101896124B1 (ko) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
SMT201900505T1 (it) 2011-03-31 2019-11-13 Adc Therapeutics Sa Anticorpi contro l'antigene 1 associato ai reni e loro frammenti leganti l'antigene
CA2857400A1 (en) 2012-01-09 2013-07-18 Alethia Biotherapeutics Inc. Anti-kaag1 antibodies or antigen binding fragment thereof for treatment of triple negative breast cancer
KR102274722B1 (ko) * 2012-08-23 2021-07-09 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체
JP5996707B2 (ja) * 2015-04-15 2016-09-21 メディミューン リミテド Ｒｓｖ特異的結合分子
TWI716405B (zh) 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
WO2017096281A1 (en) * 2015-12-02 2017-06-08 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2017096182A1 (en) * 2015-12-03 2017-06-08 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
EP3528840A1 (en) * 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3529272A2 (en) 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11485775B2 (en) 2016-10-21 2022-11-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018150029A1 (en) * 2017-02-17 2018-08-23 Institut Pasteur Generation of monoclonal antibodies targeting respiratory syncytial virus (rsv) using regulatory b cells from newborns (nbregs)
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
CA3177152A1 (en) 2020-06-12 2021-12-16 David Scott Johnson Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
KR20070038556A (ko) * 2004-07-20 2007-04-10 심포젠 에이/에스 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
EP2053408B1 (en) * 2004-07-20 2012-03-07 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
JP2009518320A (ja) * 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
KR20080113223A (ko) * 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
WO2008106980A2 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
EP2152872B1 (en) * 2007-05-25 2010-09-15 Symphogen A/S Method for manufacturing a recombinant polyclonal protein

Also Published As

Publication number Publication date
US20090137003A1 (en) 2009-05-28
RU2010113510A (ru) 2011-10-20
EP2185590A2 (en) 2010-05-19
JP2011514139A (ja) 2011-05-06
CN101821289A (zh) 2010-09-01
KR20100087283A (ko) 2010-08-04
US20120009623A1 (en) 2012-01-12
WO2009030237A2 (en) 2009-03-12
BRPI0817079A2 (pt) 2016-10-11
TW200925279A (en) 2009-06-16
WO2009030237A3 (en) 2009-04-30
CA2695309A1 (en) 2009-03-12
AU2008295248A1 (en) 2009-03-12
MX2010002044A (es) 2010-03-18

Similar Documents

Publication Publication Date Title
ZA201000756B (en) Methods for recombinant manufacturing of anti-rsv antibodies
IL205257A0 (en) Anti-rsv g protein antibodies
AP3371A (en) Anti-IGF antibodies
EP2331579A4 (en) MONOCLONAL ANTIBODIES
EP2349331A4 (en) HUMANIZED ANTIBODIES TO IL-6
ZA201005348B (en) Humanized anti-c5ar antibodies
IL229512A0 (en) Anti-vegf antibodies
ZA201008993B (en) Anti-human interleukin-20 antibodies
IL208163A0 (en) Methods for manufacturing a polyclonal protein
SG10201601279SA (en) Monoclonal Antibody STRO-4
GB0821100D0 (en) Antibodies
ZA201202227B (en) Monoclonal antibodies
IL236236A (en) Antibodies to the fam26f polypeptide
ZA201006099B (en) Anti-tyrp1 antibodies
IL240122A0 (en) A method for producing an antibody
ZA201007976B (en) Anti-pirb antibodies
EP2221384A4 (en) METHOD FOR MANUFACTURING ANTIBODY
GB0818356D0 (en) Antibodies
GB0823562D0 (en) Antibodies
GB0806230D0 (en) Antibodies